Register
A new injectable treatment for two rare types of non-Hodgkin lymphoma |
Journal Updates
eMediNexus Coverage from: 
A new injectable treatment for two rare types of non-Hodgkin lymphoma

0 Read Comments                

The US Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome after at least one prior systemic therapy. This is the first FDA approval of a drug specifically for Sézary syndrome.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now